Float Short %

18.12

Margin Of Safety %

Put/Call OI Ratio

0.37

EPS Next Q Diff

EPS Last/This Y

-0.03

EPS This/Next Y

1.36

Price

19.41

Target Price

Analyst Recom

1.25

Performance Q

376.47

Relative Volume

0.37

Beta

1.12

Ticker: URGN

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-25	URGN	18.98	0.29	0.23	35585
2025-07-28	URGN	18.88	0.29	0.77	36036
2025-07-29	URGN	18.91	0.29	1.10	36110
2025-07-30	URGN	19.21	0.30	0.03	36781
2025-07-31	URGN	19.06	0.30	0.08	36807
2025-08-01	URGN	19.4	0.30	0.10	36844
2025-08-04	URGN	19.88	0.30	0.06	37108
2025-08-05	URGN	20.7	0.30	0.27	37125
2025-08-06	URGN	20.01	0.30	0.16	36990
2025-08-07	URGN	18.66	0.31	4.26	37063
2025-08-08	URGN	17.74	0.36	0.27	38741
2025-08-11	URGN	18.12	0.36	1.01	38649
2025-08-12	URGN	19.2	0.36	0.16	38790
2025-08-13	URGN	20.12	0.36	0.55	39539
2025-08-14	URGN	20.08	0.37	0.09	39885
2025-08-15	URGN	19.74	0.38	0.34	40188
2025-08-18	URGN	19.39	0.37	0.97	28859
2025-08-19	URGN	18.9	0.37	0.41	29306
2025-08-20	URGN	19.33	0.37	0.10	29327
2025-08-21	URGN	19.77	0.37	0.06	29463
2025-08-22	URGN	19.41	0.37	0.34	29422
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-25	URGN	18.95	9.0	-	-2.88
2025-07-28	URGN	18.81	9.0	-	-2.88
2025-07-29	URGN	18.90	9.0	-	-2.88
2025-07-30	URGN	19.22	9.0	-	-2.88
2025-07-31	URGN	19.06	9.0	-	-2.88
2025-08-01	URGN	19.40	9.0	-	-2.88
2025-08-04	URGN	19.88	9.0	-	-2.88
2025-08-05	URGN	20.72	9.0	-	-2.88
2025-08-06	URGN	20.02	9.0	-	-2.88
2025-08-07	URGN	18.59	9.0	-	-2.88
2025-08-08	URGN	17.75	9.0	-	-2.88
2025-08-11	URGN	18.27	9.0	-	-2.88
2025-08-12	URGN	19.22	-10.9	-	-2.88
2025-08-13	URGN	20.11	-12.1	-	-2.88
2025-08-14	URGN	20.06	-12.1	-	-2.88
2025-08-15	URGN	19.71	-12.1	-	-2.96
2025-08-18	URGN	19.40	-12.1	-	-2.96
2025-08-19	URGN	18.92	-12.1	-	-2.96
2025-08-20	URGN	19.30	-12.1	-	-2.96
2025-08-21	URGN	19.77	-12.1	-	-2.96
2025-08-22	URGN	19.41	-14.0	-	-2.99
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-25	URGN	-0.26	28.53	18.37
2025-07-28	URGN	-0.26	29.32	18.37
2025-07-29	URGN	-0.26	29.32	18.37
2025-07-30	URGN	-0.46	29.32	18.37
2025-07-31	URGN	-0.46	29.32	18.37
2025-08-01	URGN	-0.46	29.32	18.37
2025-08-04	URGN	-0.46	32.34	18.38
2025-08-05	URGN	-0.27	32.34	18.38
2025-08-06	URGN	-0.27	32.34	18.38
2025-08-07	URGN	-0.27	32.34	18.38
2025-08-08	URGN	-0.27	32.34	18.38
2025-08-11	URGN	-0.27	31.57	18.35
2025-08-12	URGN	-0.27	31.57	18.03
2025-08-13	URGN	-0.42	31.57	18.03
2025-08-14	URGN	-0.42	31.57	18.03
2025-08-15	URGN	-0.43	31.57	18.03
2025-08-18	URGN	-0.43	42.69	18.12
2025-08-19	URGN	-0.41	42.69	18.12
2025-08-20	URGN	-0.41	42.69	18.12
2025-08-21	URGN	-0.41	42.69	18.12
2025-08-22	URGN	-0.41	42.69	18.12
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.63

Avg. EPS Est. Next Quarter

-0.39

Insider Transactions

-0.41

Institutional Transactions

42.69

Beta

1.12

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

31.2

Max Drawdown 5-Year %

-85.4

Target Price

P/E

Forward P/E

PEG

P/S

9.54

P/B

P/Free Cash Flow

EPS

-3.32

Average EPS Est. Cur. Y

-2.99

EPS Next Y. (Est.)

-1.63

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-164.44

Relative Volume

0.37

Return on Equity vs Sector %

273.3

Return on Equity vs Industry %

286.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.11

EBIT Estimation

UroGen Pharma Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 253

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today

news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025

marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance

stock history URGN – UroGen Pharma Ltd. invest stock market

stock prices URGN premarket after hours

ticker URGN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: URGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y